Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2974153 | 0.89 | SPHK2 (0.49) | SPHK2SPHK1HRH3ADRA1DADRA1A | |
| SCHEMBL4139443 | 0.83 | HRH3 (0.68) | SPHK2SPHK1HRH3HTR1DHTR1B | |
| SCHEMBL27191666 | 0.79 | HTR1D (0.67) | HTR1DHTR1B | |
| SCHEMBL27206330 | 0.79 | HTR1D (0.67) | HTR1DHTR1B | |
| SCHEMBL2989574 | 0.78 | CYP1A2 (0.45) | HRH3 | |
| SCHEMBL2983763 | 0.77 | SPHK2 (0.38) | SPHK2SPHK1HRH3 | |
| SCHEMBL2983761 | 0.77 | GBA1 (0.48) | HRH3 | |
| SCHEMBL2987008 | 0.75 | SPHK2 (0.52) | SPHK2SPHK1HRH3ADRA1DADRA1A | |
| SCHEMBL27627908 | 0.72 | SPHK2 (0.66) | SPHK2SPHK1HRH3 | |
| SCHEMBL27191697 | 0.71 | HTR2A (0.62) | HRH3HTR1DHTR1BPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | BIODERM RESEARCH (US) | 2009-03-19 | — | — | US | claimed |
| US-7777073-B2 | Topical delivery system for antiaging and skin whitening agents | BIODERM RESEARCH (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | BIODERM RESEARCH (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | TYR, MMP17, MMP1 | SPHK2 2315/4885SPHK1 2052/4885HRH3 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.